Costs of Trastuzumab in Combination With Chemotherapy for HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: An Economic Evaluation in the Chinese Context

Clinical Therapeutics

Volumn 34, Issue 2, 2012, Pages 468-479

  Wu, Bin ^a   Ye, Ming ^a   Chen, Huafeng ^a   Shen, Jinfang F ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Advanced gastric cancer; Chemotherapy; Cost effectiveness; Trastuzumab

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROPYRIMIDINE; FLUOROURACIL; TRASTUZUMAB;

ADVANCED CANCER; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHINA; COST EFFECTIVENESS ANALYSIS; DRUG COST; ESOPHAGUS CANCER; GASTROESOPHAGEAL JUNCTION CANCER; GASTROINTESTINAL DISEASE; HEALTH CARE UTILIZATION; HUMAN; NEUTROPENIA; OVERALL SURVIVAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STOMACH CANCER; SURVIVAL TIME; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL, HUMANIZED; COST-BENEFIT ANALYSIS; ESOPHAGOGASTRIC JUNCTION; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84863052834     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.01.012     Document Type: Article

References (34)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Shin H.R., Masuyer E., Ferlay J., Curado M.P. Cancer in Asia-Incidence rates based on data in cancer incidence in five continents IX (1998-2002). Asian Pac J Cancer Prev 2010, 11(Suppl 2):11-16.
3. Wagner A.D., Grothe W., Haerting J., et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006, 24:2903-2909.
4. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150.
5. De Vita F., Giuliani F., Silvestris N., et al. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev 2010, 36(Suppl 3):S11-S15.
6. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
7. Multicenter study on HER-2/new gene amplification and protein expression in patients with gastric cancer. Chinese Journal of Digestive Diseases 2006, 26:657-660. Cooperative Study Group of HER2 in China.
8. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
9. Li X.D., Shen H., Jiang J.T., et al. Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer. World J. Gastroenterol 2011, 17:1082-1087.
10. Luo H.Y., Xu R.H., Wang F., et al. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. Chemotherapy 2010, 56:94-100.
11. Kodera Y., Ito S., Mochizuki Y., et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res 2007, 27:2667-2671.
12. Shitara K., Matsuo K., Takahari D., et al. Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel. Ann Oncol 2010, 21:2403-2409.
13. Hironaka S., Zenda S., Boku N., et al. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 2006, 9:14-18.
14. Wilson D., Hiller L., Geh J.I. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol) 2005, 17:81-90.
15. Sakamaki H., Ikeda S., Yajima S., et al. Cost-utility analysis of the oral fluoropyrimidine s-1 versus conventional intravenous chemotherapy in advanced or recurrent gastric cancer. Open Health Serv Policy J 2009, 2:26-33.
16. National Development and Reform Commission, Accessed October 2011. http://en.ndrc.gov.cn/.
17. Common terminology criteria for adverse events US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Accessed October 2011. http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
18. Murray C.J., Evans D.B., Acharya A., Baltussen R.M. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 2000, 9:235-251.
19. Eichler H.G., Kong S.X., Gerth W.C., et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. Value Health 2004, 7:518-528.
20. Proportions of males and females in China Accessed January 2011. http://www.gov.cn/gzdt/2006-03/16/content_228740.htm.
21. Census data in China Accessed January 2012. http://zwgk.chinapop.gov.cn/auto226/201108/t20110817_369788.html.
22. Catalano V., Graziano F., Santini D., et al. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?. Br J Cancer 2008, 99:1402-1407.
23. Cleemput I., Neyt M., Thiry N., et al. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Technol Assess Health Care 2011, 27:71-76.
24. Li L. The challenges of healthcare reforms in China. Public Health 2011, 125:6-8.
25. Hougaard J.L., Osterdal L.P., Yu Y. The Chinese healthcare system: structure, problems and challenges. Appl Health Econ Health Policy 2011, 9:1-13.
26. Wagstaff A., Yip W., Lindelow M., Hsiao W.C. China's health system and its reform: a review of recent studies. Health Econ 2009, 18(Suppl 2):S7-S23.
27. Matter-Walstra K.W., Dedes K.J., Schwenkglenks M., et al. Trastuzumab beyond progression: a cost-utility analysis. Ann Oncol 2010, 21:2161-2168.
28. Chan A.L., Leung H.W., Lu C.L., Lin S.J. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review. Ann Pharmacother 2009, 43:296-303.
29. McKeage K., Lyseng-Williamson K.A. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer. Pharmacoeconomics 2008, 26:699-719.
30. Lidgren M., Jonsson B., Rehnberg C., et al. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol 2008, 19:487-495.
31. Kang Y.K., Kang W.K., Shin D.B., et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009, 20:666-673.
32. Wagner A.D., Unverzagt S., Grothe W., et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010, CD004064.
33. Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007, 357:1810-1820.
34. Montagnani F., Turrisi G., Marinozzi C., et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer 2011, 14:50-55.